{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreic4txscrdkhohkqkyuzt7xbcbmlzqpem23rohlcjw57w3wd2i5yxm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mh727bycogk2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihs4yniv5gslv4xxwpwazmdqvpsj3sble4olz6hvbzdguafle3ihy"
    },
    "mimeType": "image/jpeg",
    "size": 123080
  },
  "path": "/pharmalot/2026/03/16/pharmalittle-obesity-pill-trial-results-new-cholesterol-guidelines/?utm_campaign=rss",
  "publishedAt": "2026-03-16T13:18:08.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Pharma",
    "Pharmalot",
    "pharmalittle",
    "STAT+"
  ],
  "textContent": "Structure Therapeutics disclosed that its daily obesity pill led patients to lose about 16% of their body weight relative to placebo after 44 weeks",
  "title": "STAT+: Pharmalittle: We’re reading about obesity pill trial results, cholesterol guidelines, and more",
  "updatedAt": "2026-03-16T13:18:12.000Z"
}